All prices are in US$. Prices are given both for a yearly adult dose and by unit.
For details on eligibility and offer restrictions for countries and institutions, please refer to table 2b.
Products on the WHO list of Pilot Procurement, Quality and Sourcing Project: Access to HIV/AIDS drugs and diagnostics of acceptable quality (Sixth edition, 5th May 2003) are in bold and have an asterisk* next to the price. Always check website for most recently updated list. Best prices are in bold & underlined. Incoterms vary according to manufacturers.
Annual cost is calculated according to the daily doses given in the WHO ‘Scaling-up Antiretroviral Therapy in Resource Limited Settings: Guidelines for a Public Health Approach’ (June 2002) and/or the ‘Guidelines for the Use of Antiretroviral Agents in HIV Infected Adults and Adolescents’ from the Panel on Clinical Practices for the Treatment of HIV (2002).
NNRTI
(Abbreviation) |
efavirenz
(EFV) |
efavirenz
(EFV) |
nevirapine
(NVP) |
Strength (mg) |
200 |
600 |
200 |
Trade name in Europe/US |
Stocrin® or Sustiva®
(Merck & Co., Inc.)(**) |
Stocrin® or Sustiva®
(Merck & Co., Inc.)(**) |
Viramune®
(Boehringer-Ingelheim) |
Daily dose |
3 |
1 |
2 |
Boehringer-Ingelheim
(Germany) |
|
|
438*
(0.600/unit) |
Merck & Co., Inc.
(US) |
500
(0.457/unit)(†) |
346.75
(0.950/unit)(†) |
|
Aurobindo
(India) |
438
(0.400/unit) |
|
112
(0.153/unit) |
Cipla
(India) |
462
(0.422/unit) |
462
(1.267/unit) |
208*
(0.285/unit) |
GPO
(Thailand) |
|
|
244
(0.334/unit) |
Hetero
(India) |
548
(0.500/unit) |
|
105
(0.144/unit) |
Ranbaxy
(India) |
|
578
(1.583/unit) |
166*
(0.228/unit) |
(**) Known as Sustiva® (BMS) in US, Canada, UK, Republic of Ireland, France, Spain, Italy and Germany.
(†) Prices given in this table are for Low Human Development Index (HDI) countries plus medium HDI countries with adult HIV prevalence of 1% or greater.
In table 2b, prices for medium HDI countries with adult HIV prevalence less than 1%, are given.
Loading...
